- Home
- UNCY vs RDI Comparison
UNCY vs RDI Comparison
Compare UNCY & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- RDI
- Stock Information
- Founded
- UNCY 2016
- RDI 1937
- Country
- UNCY United States
- RDI United States
- Employees
- UNCY N/A
- RDI N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- RDI Movies/Entertainment
- Sector
- UNCY Health Care
- RDI Consumer Discretionary
- Exchange
- UNCY Nasdaq
- RDI Nasdaq
- Market Cap
- UNCY 31.9M
- RDI 32.3M
- IPO Year
- UNCY 2021
- RDI N/A
- Fundamental
- Price
- UNCY $0.66
- RDI $1.43
- Analyst Decision
- UNCY Strong Buy
- RDI Hold
- Analyst Count
- UNCY 4
- RDI 1
- Target Price
- UNCY $5.50
- RDI $2.40
- AVG Volume (30 Days)
- UNCY 1.5M
- RDI 43.9K
- Earning Date
- UNCY 11-13-2024
- RDI 11-14-2024
- Dividend Yield
- UNCY N/A
- RDI N/A
- EPS Growth
- UNCY N/A
- RDI N/A
- EPS
- UNCY N/A
- RDI N/A
- Revenue
- UNCY N/A
- RDI $197,270,000.00
- Revenue This Year
- UNCY N/A
- RDI N/A
- Revenue Next Year
- UNCY N/A
- RDI $14.40
- P/E Ratio
- UNCY N/A
- RDI N/A
- Revenue Growth
- UNCY N/A
- RDI N/A
- 52 Week Low
- UNCY $0.20
- RDI $1.22
- 52 Week High
- UNCY $1.82
- RDI $2.15
- Technical
- Relative Strength Index (RSI)
- UNCY 52.04
- RDI 45.67
- Support Level
- UNCY $0.62
- RDI $1.43
- Resistance Level
- UNCY $0.87
- RDI $1.59
- Average True Range (ATR)
- UNCY 0.08
- RDI 0.09
- MACD
- UNCY -0.01
- RDI -0.01
- Stochastic Oscillator
- UNCY 15.45
- RDI 7.69
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.